SUBSTITUTED AZETIDINYL COMPOUNDS AS GLYT1 INHIBITORS

The invention provides a chemical entity of Formula (I) wherein R1, R2, R3, R4, X, and Y have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies; de...

Full description

Saved in:
Bibliographic Details
Main Authors Santora Vincent, Basinger Jillian, Hudson Andrew, Bookser Brett, Chen Mi, Renick Joel, Na James
Format Patent
LanguageEnglish
Published 23.11.2017
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The invention provides a chemical entity of Formula (I) wherein R1, R2, R3, R4, X, and Y have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive treatments; modulating and treating disorders mediated by GlyTl activity; treating neurological disorders, CNS disorders, dementia, neurodegenerative diseases, and trauma-dependent losses of function; treating stroke, including cognitive and motor deficits during stroke rehabilitation; facilitating neuroprotection and neurorecovery; enhancing the efficiency of cognitive and motor training, including animal skill training; and treating other disorders, including pain and alcohol-dependence.
Bibliography:Application Number: US201515524548